Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24387115 | 0.79 | SLC6A2 (0.43) | SLC6A2SLC6A4BLMSLC6A3MEN1 | |
| SCHEMBL24387541 | 0.79 | SLC6A2 (0.43) | SLC6A2SLC6A4BLMSLC6A3MEN1 | |
| SCHEMBL29220480 | 0.77 | RIPK1 (0.30) | RIPK1 | |
| Hydrochloric Acid SCHEMBL29750304 | 0.77 | SLC6A2 (0.41) | SLC6A2SLC6A4BLMSLC6A3MEN1 | |
| SCHEMBL20763612 | 0.75 | — | — | |
| SCHEMBL20763832 | 0.73 | — | — | |
| SCHEMBL20763597 | 0.73 | RIPK1 (0.31) | RIPK1 | |
| SCHEMBL28060797 | 0.73 | MEN1 (0.43) | SLC6A2SLC6A4BLMSLC6A3MEN1 | |
| SCHEMBL29433246 | 0.72 | — | — | |
| SCHEMBL1485878 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190055279-A1 | NOVEL POLYPEPTIDES WITH IMPROVED PROTEOLYTIC STABILITY, AND METHODS OF PREPARING AND USING SAME | TUFTS UNIVERSITY (US) | 2019-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190055279-A1 | NOVEL POLYPEPTIDES WITH IMPROVED PROTEOLYTIC STABILITY, AND METHODS OF PREPARING AND USING SAME | PTMS, ANPEP, DNPEP | SLC6A2 4823/4885SLC6A4 4653/4885BLM 3356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.